We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+3.6%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$955M
AUM Growth
+$74.9M
Cap. Flow
+$18.7M
Cap. Flow %
1.96%
Top 10 Hldgs %
28.16%
Holding
94
New
8
Increased
32
Reduced
32
Closed
4

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$11.3M
2
BDX icon
Becton Dickinson
BDX
+$9.95M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$8.64M
4
TMO icon
Thermo Fisher Scientific
TMO
+$8.62M
5
MDT icon
Medtronic
MDT
+$8.09M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$13.6M
2
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$13M
3
CI icon
Cigna
CI
+$10.1M
4
PFE icon
Pfizer
PFE
+$9.23M
5
ELV icon
Elevance Health
ELV
+$8.13M

Sector Composition

Rank Sector Weight
1 Healthcare 98.85%
2 Industrials 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCM
51
DELISTED
R1 RCM Inc. Common Stock
RCM
$6.67M 0.7%
378,000
+53,000
+16% +$1.21M
IMGN
52
DELISTED
Immunogen Inc
IMGN
$6.53M 0.68%
1,100,000
-100,000
-8% -$527K
SWAV
53
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$5.86M 0.61%
20,000
-50,978
-72% -$13M
VEEV icon
54
Veeva Systems
VEEV
$38.6B
$5.79M 0.61%
34,500
-3,500
-9% -$699K
ITCI
55
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$5.71M 0.6%
125,000
-15,000
-11% -$784K
OM icon
56
Outset Medical
OM
$89.7M
$5.28M 0.55%
22,667
+10,667
+89% +$2.86M
SGEN
57
DELISTED
Seagen Inc. Common Stock
SGEN
$5.21M 0.55%
41,000
-4,208
-9% -$686K
AGL icon
58
Agilon Health
AGL
$1.61B
$5.06M 0.53%
10,200
+3,600
+55% +$2.16M
GKOS icon
59
Glaukos
GKOS
$10.7B
$4.77M 0.5%
85,000
-4,991
-6% -$258K
IOVA icon
60
Iovance Biotherapeutics
IOVA
$2.93B
$4.76M 0.5%
510,000
-20,000
-4% -$231K
NVST icon
61
Envista
NVST
$4.57B
$4.75M 0.5%
+143,800
New +$5.45M
KRTX
62
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$4.39M 0.46%
+20,000
New +$4.05M
VRAY
63
DELISTED
ViewRay, Inc.
VRAY
$4.29M 0.45%
1,000,000
– –
MGTX icon
64
MeiraGTx Holdings
MGTX
$1.2B
$4.04M 0.42%
555,030
+55,030
+11% +$485K
PGNY icon
65
Progyny
PGNY
$2.09B
$4M 0.42%
90,000
– –
GTHX
66
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3.94M 0.41%
370,000
+53,863
+17% +$615K
WST icon
67
West Pharmaceutical
WST
$24.6B
$3.91M 0.41%
+17,000
New +$5.18M
TDOC icon
68
Teladoc Health
TDOC
$1.28B
$3.85M 0.4%
130,000
+45,000
+53% +$1.58M
NTRA icon
69
Natera
NTRA
$45.9B
$3.76M 0.39%
+80,000
New +$3.81M
ALHC icon
70
Alignment Healthcare
ALHC
$2.77B
$3.64M 0.38%
+274,950
New +$4.01M
SGMO
71
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.6M 0.38%
820,000
+120,000
+17% +$616K
OLK
72
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$3.56M 0.37%
194,390
+54,390
+39% +$834K
ALLO icon
73
Allogene Therapeutics
ALLO
$735M
$3.5M 0.37%
340,000
-10,000
-3% -$136K
PHR icon
74
Phreesia
PHR
$779M
$3.42M 0.36%
125,000
+50,000
+67% +$1.25M
ALKS icon
75
Alkermes
ALKS
$8.26B
$3.4M 0.36%
150,000
– –
1 2
3
4

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2022 Portfolio in Review

As of Q3 2022, Rhenman & Partners Asset Management held 94 positions worth $955M, up 8.5% from $880M the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rhenman & Partners Asset Management's Q3 2022 filing shows 8 new, 32 increased, 32 reduced and 4 closed positions. Its largest new stake was Insulet: 29,000 shares worth $7.5M. The largest sale was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $13.6M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Industrials.

  • Rhenman & Partners Asset Management's largest Q3 2022 buy was Insulet: 29,000 shares worth $7.5M.
  • Rhenman & Partners Asset Management added most to Regeneron Pharmaceuticals in Q3 2022, an estimated $11.3M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2022 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $13.6M.
  • Rhenman & Partners Asset Management fully exited Align Technology in Q3 2022, selling an estimated $4.26M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 28% of its $955M portfolio in Q3 2022.
  • Rhenman & Partners Asset Management opened 8 new positions and closed 4 in Q3 2022.
  • Rhenman & Partners Asset Management's portfolio value rose 8.5% quarter-over-quarter to $955M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.